Oxygen Compound Of Arsenic Patents (Class 424/623)
-
Publication number: 20120294955Abstract: A method of inhibiting, preventing, or reducing damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents.Type: ApplicationFiled: May 18, 2011Publication date: November 22, 2012Inventor: Zhi-Min Yuan
-
Publication number: 20120251628Abstract: Compositions and methods for treating solid tumors are provided. Intraperitoneal administration of sodium meta arsenite, alone or in combination with an anti-cancer agent, results in tumor necrosis and delayed tumor growth. A particularly effective treatment for colon and rectal cancer is a combination of sodium meta arsenite administered intraperitoneally and irinotecan.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Inventor: Young Joo MIN
-
Patent number: 8273379Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Type: GrantFiled: December 21, 2010Date of Patent: September 25, 2012Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
-
Publication number: 20120225779Abstract: A pesticidal composition comprising a pesticide, an ammonium salt, and a nonionic surfactant, is provided.Type: ApplicationFiled: May 18, 2012Publication date: September 6, 2012Applicant: Dow AgroSciences LLCInventors: Jonathan M. Babcock, Steven P. Nolting
-
Patent number: 8246983Abstract: The present invention relates to methods and compositions for the treatment of cancer and for research and analysis of cancer. In particular, the present invention provides encapsulated arsenic anti-cancer compositions with improved properties.Type: GrantFiled: September 5, 2006Date of Patent: August 21, 2012Assignee: Northwestern UniversityInventors: Thomas O'Halloran, Haimei Chen
-
Publication number: 20120195890Abstract: Oligonucleotides inhibiting cellular migration, and the use of at least one inhibitor of protein expression, which inhibits the expression of TSP1 protein, or a protein, which controls the expression of TSP1 or mediates the activity of TSP1, or one inhibitor of protein activity, this inhibitor inhibiting the activity of the TSP1 protein, in particular the activity responsible for the stimulation of cell migration, or one protein which controls the expression or mediates the activity of TSP1 for the manufacture of a drug for the prevention or the treatment of primary tumors or invasive or metastatic tumors.Type: ApplicationFiled: July 30, 2010Publication date: August 2, 2012Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Florence Cabon, Virginie Firlej, Catherine Gallou-Kabani, Natalia Catherine Prevarskaya
-
Publication number: 20120164065Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: January 11, 2012Publication date: June 28, 2012Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20120134955Abstract: The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a —(C?O)aOb(C1-C6)alkyl group, a —(C?O)aOb(C2-C6)alkenyl group, a —(C?O)aOb(C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R2 and R3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a —(C?O)aOb(C1-C6)alkyl group or a group of —(C?O)aN(R1e)R2e; R4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee 1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.Type: ApplicationFiled: February 18, 2010Publication date: May 31, 2012Inventors: Yasuhiro Goto, Kenji Niyama, Satoshi Sunami, Keiji Takahashi
-
Publication number: 20120128791Abstract: Disclosed herein is a composition concentrate that is suitable for treating wood upon dilution with water in a weight ratio of concentrate to water of between 1:10 and 1:100. The concentrate contains copper ammonium cations, zinc ammonium cations, arsenate and/or hydrogen arsenate anions; carbonate and/or bicarbonate anions, ammonia and water, wherein the total amount of copper and zinc is from 17% to about 22% by weight based on the total volume of the concentrate. Also disclosed is a process for producing ammoniacal copper zinc arsenate concentrate.Type: ApplicationFiled: October 13, 2011Publication date: May 24, 2012Inventors: Jayesh P. Patel, Gloriana Kuswanto
-
Publication number: 20120114739Abstract: The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.Type: ApplicationFiled: April 8, 2010Publication date: May 10, 2012Inventors: Yongqi Deng, Binyuan Sun, Hongbo Zeng, Matthew Richards, Gerald W. Shipps, JR., Cliff C. Cheng, Yinyan Zhao, Andrew McRiner, Zhaoyang Meng, Yang Nan, Mehul F. Patel, Iwona E. Wrona, Panduranga Adulla Reddy, Brian M. Eklov, Shuyi Tang, Duan Liu, Amit K. Mandal, Lianyun Zhao, M. Asshad Siddiqui
-
Publication number: 20120093917Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical inhibitors of DNA repair proteins (Metnase) and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols.Type: ApplicationFiled: March 31, 2010Publication date: April 19, 2012Inventors: Robert Hromas, Andrei Leitao, Tudor I. Oprea, Larry A. Sklar, Elizabeth A. Williamson, Justin Wray
-
Publication number: 20120058201Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.Type: ApplicationFiled: April 5, 2010Publication date: March 8, 2012Applicant: VANDA PHARMACEUTICALS, INC.Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
-
Publication number: 20120045520Abstract: A method for using a salt of meta-arsenite (AsO2—) to suppress growing of human cancer cells is provided to find a method of curing human cancers. Effects of the salt of meta-arsenite (AsO2—) on various human cancer cells are investigated via in vitro cytotoxic activity and in vivo anticancer activity against nude mice. For in vitro cytotoxic activity, six (6) kinds of human cancer with nine (9) cancer cell lines, eight (8) kinds of human cancers with twelve (12) cancer cell lines and ten (10) kinds of human cancers with forty one (41) cancer cell lines are tested. For in vivo anticancer activity, two (2) kinds of cancers of human renal cancer RXF 944LX and leukemia cells are tested utilizing nude mice.Type: ApplicationFiled: October 31, 2011Publication date: February 23, 2012Inventor: Sang Bong LEE
-
Publication number: 20120045519Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Applicant: Academia SinicaInventors: Lie-Fen SHYUR, Wen-Wan Chao, Ya-Wen Cheng
-
Publication number: 20120027871Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.Type: ApplicationFiled: April 5, 2010Publication date: February 2, 2012Applicant: VANDA PHARMACEUTICALS, INC.Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
-
Publication number: 20110311648Abstract: Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.Type: ApplicationFiled: July 20, 2011Publication date: December 22, 2011Inventors: George C. Prendergast, Alexander J. Muller, James B. DuHadaway, William Malachowski
-
Publication number: 20110305774Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.Type: ApplicationFiled: October 29, 2009Publication date: December 15, 2011Applicant: ISTITUTO SUPERIORE DI SANITAInventors: Andrea Savarino, Marina Lusic, Antonello Mai, Anna Teresa Palamara, Enrico Garaci
-
Publication number: 20110256236Abstract: The cytotoxic effects of thalidomide are enhanced when it is used in combination with other chemotherapeutic agents, particularly arsenic trioxide, indicating benefits for the treatment of blood-related cancers, especially acute myelogenous leukemia.Type: ApplicationFiled: April 16, 2010Publication date: October 20, 2011Inventors: Erian Girgis, Magdi Soliman
-
Publication number: 20110250291Abstract: A method of inhibiting damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents.Type: ApplicationFiled: November 12, 2010Publication date: October 13, 2011Inventor: Zhi-Min Yuan
-
Publication number: 20110250292Abstract: Disclosed is a composition for improving radiotherapy for cancer, containing tetra-arsenic oxide (As4O6) as an active ingredient. The disclosed composition for improving radiotherapy for cancer improves the efficiency of radiotherapy, and thus reduces side effects caused by the high-dose radiation. The disclosed composition uses tetra-arsenic oxide, the safety of which is proven, from among conventional arsenic compound derivatives, to prevent side effects caused by arsenic trioxide, taxol, cisplatin, fluorouracil, leuprolide, or the like, which are known as conventional radiosensitizers.Type: ApplicationFiled: November 30, 2009Publication date: October 13, 2011Applicant: CHONJISAN CO., LTD.Inventors: Ill Ju Bae, Sae Gwang Park
-
Publication number: 20110244027Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.Type: ApplicationFiled: May 13, 2011Publication date: October 6, 2011Applicant: University of Georgia Research CenterInventors: Chung K. Chu, Jianing Wang
-
Publication number: 20110243891Abstract: The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Weel kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.Type: ApplicationFiled: December 9, 2009Publication date: October 6, 2011Inventors: Makoto Bamba, Hidetomo Furuyama, Toshihiro Sakamoto, Satoshi Sunami, Keiji Takahashi, Fuyuki Yamamoto, Takashi Yoshizumi
-
Publication number: 20110206756Abstract: Described herein are compositions useful in anticancer treatment and prevention. The compositions are composed of (a) a dithiocarbamate metal chelate and (b) an amphiphile, wherein the amount of amphiphile is sufficient to produce a liposome or micelle. Methods for using the compositions in anticancer treatment and prevention are also described herein.Type: ApplicationFiled: March 16, 2009Publication date: August 25, 2011Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Paul J. Shami, Ken M. Kosak, Thomas Kennedy
-
Publication number: 20110200684Abstract: Synergistic pesticidal mixtures are provided.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: DOW AGROSCIENCES LLCInventors: Jim X. Huang, Jonathan M. Babcock, Thomas Meade, Marc Farrow
-
Publication number: 20110195110Abstract: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.Type: ApplicationFiled: December 1, 2006Publication date: August 11, 2011Inventors: Roger Smith, Holia N. Hatoum-Mokdad, Louis David Cantin, Donald E. Bierer, Wenlang Fu, Dhanapalan Nagarathnam, Gaetan Ladouceur, Yamin Wang, Herbert Ogutu, Scot Wilhelm, Ian Taylor, Sanjeeva Reddy, Richard Gedrich, Christopher Carter, Aaron Schmitt, Xiaomei Zhang
-
Publication number: 20110151020Abstract: The present invention refers to active substance combinations comprising of a nucleoside analog or antimetabolic agent like Gemcitabine, and either a Nodal/Activin inhibitor or a SHH-Inhibitor and an mTOR-inhibitor, medicaments comprising the same and the use of the active substance combinations in the treatment of cancer, especially of epithelial cancer.Type: ApplicationFiled: September 13, 2010Publication date: June 23, 2011Inventors: CHRISTOPHER HEESCHEN, MARIA THERESA MÜLLER, PATRICK CHRISTIAN HERMANN, STEPHAN HUBER
-
Publication number: 20110135601Abstract: The invention relates to a compound of a general formula (I): wherein A1 and A2 each mean a nitrogen atom or an optionally-substituted methine group; Ring B means a 5-membered to 7-membered aliphatic ring, or a spiro or bicyclo ring formed from the aliphatic ring and any other 3-membered to 7-membered aliphatic ring; R1 means a hydrogen atom, or an optionally-substituted C1-C6 alkyl group, or an optionally-substituted aryl, aralkyl or heteroaryl group; R2 means an optionally-substituted aryl, aralkyl or heteroaryl group; and X means a group of ?NH or ?O, etc. Based on its excellent Wee1 kinase-inhibitory effect, the compound of the invention has cell growth-inhibitory effect and has an additive/synergistic effect with any other anticancer agent, and is therefore useful in the field of medicine.Type: ApplicationFiled: June 12, 2008Publication date: June 9, 2011Inventor: Makoto Bamba
-
Publication number: 20110104108Abstract: The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R8 is independently H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: YALE UNIVERSITYInventor: Yung-Chi CHENG
-
Publication number: 20110091573Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Type: ApplicationFiled: December 21, 2010Publication date: April 21, 2011Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Raymond P. Warrell, JR., Pier Paolo Pandolfi, Janice L. Gabrilove
-
Publication number: 20110070314Abstract: The present invention relates to methods treating brain tumors comprising administering a subject in need thereof a therapeutically effective amount of sodium meta arsenite, alone or in combination with another anti-brain tumor medicament.Type: ApplicationFiled: September 10, 2010Publication date: March 24, 2011Inventors: Yong Joon Jo, Yong Jin Yang
-
Publication number: 20110059186Abstract: The present invention provides methods for preventing, treating, and/or managing cancer, the method comprising administering to a subject in need thereof therapeutically effective amount of sodium meta arsenite that reduces or eliminates drug resistant cancer stem cell populations as well as drug resistant mature cancer cells.Type: ApplicationFiled: September 10, 2010Publication date: March 10, 2011Inventor: Angelika BURGER
-
Patent number: 7879364Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Type: GrantFiled: September 30, 2005Date of Patent: February 1, 2011Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
-
Publication number: 20110020434Abstract: The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.Type: ApplicationFiled: September 8, 2010Publication date: January 27, 2011Inventors: Thomas V. O'Halloran, Haimei Chen, Andrew Mazar
-
Publication number: 20100323002Abstract: The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer.Type: ApplicationFiled: February 5, 2010Publication date: December 23, 2010Applicant: NEW YORK UNIVERSITYInventors: Peter C. Brooks, Danielle Morais, Dorothy Rodriguez
-
Publication number: 20100291234Abstract: Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of inflammatory arthritis involves administering a formulation containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide formulation can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule.Type: ApplicationFiled: May 18, 2010Publication date: November 18, 2010Inventor: YOK-LAM KWONG
-
Publication number: 20100291025Abstract: The present invention relates to new indazole inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 13, 2010Publication date: November 18, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20100278937Abstract: The present invention relates to methods and materials for killing cancer cells with proteins derived from bacteria. The invention specifically relates to Azurin, Laz, Pa-CARD, and fusion proteins Azu-H.8 and H.8-Azu, and their use in killing leukemia cells and/or ovarian cancer cells.Type: ApplicationFiled: February 22, 2010Publication date: November 4, 2010Inventors: Tapas K. Das Gupta, Ananda Chakrabarty, Arsenio Fialho
-
Publication number: 20100266674Abstract: The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, of which property requires a high and frequent dosage for an intravenous administration. Unlike other nucleoside anti-tumor agents, troxacitabine appears to predominantly enter tumor cells by passive diffusion rather then by using nucleoside transporters, although this may be model dependent. Accordingly, in the present work, a small library of twenty troxacitabine prodrugs has been synthesized using a parallel approach in order to evaluate the relationship between the lipophilicity of the prodrugs and their antitumor activity. Biological evaluation of the prodrugs on two non-small cell lung cancer cell lines (A549 and SW1573) and in pancreatic cell lines clearly showed better antitumor activity than that of troxacitabine, with IC50 values in the nanomolar range.Type: ApplicationFiled: August 30, 2007Publication date: October 21, 2010Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventor: David C.K. Chu
-
Publication number: 20100260813Abstract: A rodenticidal mixture comprising a) 0.0015 to 99.89% by weight of at least one rodenticide, b) 10?8 to 95% by weight of at least one painkiller and c) 0.01 to 99.9984% by weight of at least one biocide, where the percentages by weight are based on the total of components (a), (b) and (c), is suitable for the preparation of rodenticidal bait formulations which are employed for controlling rodent pests.Type: ApplicationFiled: September 30, 2008Publication date: October 14, 2010Applicant: BASF SEInventors: Gerhard Schnabel, Michael Ishaque, Dieter Zeller, Lars Weichel, Andrej Brejc
-
Publication number: 20100260864Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.Type: ApplicationFiled: April 14, 2010Publication date: October 14, 2010Applicant: Florida Atlantic UniversityInventors: Herbert Weissbach, Lionel Resnick, David Binninger
-
Publication number: 20100247603Abstract: An arsenic trioxide medical elution scaffold and preparation method thereof, wherein the arsenic trioxide medical elution scaffold comprises scaffold, polymer coating covering the scaffold and arsenic trioxide loaded in the polymer coating which is in the form of single particle or particle conglomeration island. Animal experiments testify that the medical release of the arsenic trioxide medical elution scaffold is suitably uniform, and can be controlled to meet clinic requirement.Type: ApplicationFiled: April 21, 2008Publication date: September 30, 2010Applicant: BEIJING AMSINO MEDICAL CO., LTDInventors: Junbo Ge, Xiaoyi Ma
-
Patent number: 7803350Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.Type: GrantFiled: July 30, 2007Date of Patent: September 28, 2010Assignees: Institute of Nuclear Energy Research Rocaec, TTY Biopharm Company, LimitedInventors: Te-Wei Lee, Chun-Ying Huang, Ming-Shiuan Wu, Te-Jung Chen, Kwo-Ping Chang, Shiang-Rong Chang, Shyh-Yi Chyi, Chih-Hsien Chang, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao
-
Publication number: 20100233166Abstract: Compounds, compositions and methods for the treatment of malignancy are disclosed.Type: ApplicationFiled: April 13, 2010Publication date: September 16, 2010Inventors: George C. Prendergast, Alexander J. Muller, James B. Duhadaway, William Malachowski
-
Publication number: 20100221211Abstract: The invention relates to a compound of general formula (I-0): wherein R1 means a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or a C3-C6 cycloalkyl group; R2, R3, R4 and R5 mean a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a C1-C6 alkoxy group, or a halo-C1-C6 alkoxy group; R6 means a hydrogen atom, or a C1-C6 alkyl group; R7a means a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxy-C1-C6 alkyl group, -Q2-N(R1c)R1d or a nitrogen-containing heterocyclic group; R8a means a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a C1-C6 alkoxy group or a hydroxy-C1-C6 alkyl group; or R7a and R8a form, as taken together, a C2-C6 alkylene group, or R7a and R8a and the ring atoms to which they bond may form a spiro ring or a bicyclo ring; and X and Y mean a methine group or a nitrogen atom.Type: ApplicationFiled: October 20, 2008Publication date: September 2, 2010Inventors: Hidetomo Furuyama, Mikako Kawamura, Toshihiro Sakamoto, Fuyuki Yamamoto, Takashi Yoshizumi
-
Publication number: 20100209431Abstract: The present invention relates to a metal triangulo compound. Provided is also a method of inducing apoptosis in a cell that comprises administering the metal triangulo compound. Provided is also a method of preventing carcinogenesis in a cell that comprises administering the metal triangulo compound.Type: ApplicationFiled: April 4, 2008Publication date: August 19, 2010Inventors: Shazib Pervaiz, Sanjiv Kumar Yadav
-
Publication number: 20100189683Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.Type: ApplicationFiled: December 10, 2009Publication date: July 29, 2010Applicant: Ascenta Therapeutics, Inc.Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
-
Publication number: 20100166881Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.Type: ApplicationFiled: March 11, 2010Publication date: July 1, 2010Inventors: George C. Prendergast, William P. Malachowski, Alexander J. Muller, James B. DuHadaway
-
Publication number: 20100143296Abstract: The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 10, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100135903Abstract: The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a metastatic neoplastic tumour in a localised manner by effecting the exposure of neoplastic cell intra-cellular molecules, preferably intra-nuclear molecules, suitable for use as a therapeutic target. The co-localisation of tumour cells and metastases to discrete tissue locations thereby renders the method of the present invention useful in terms of the delivery of bystander-based therapy.Type: ApplicationFiled: October 11, 2007Publication date: June 3, 2010Applicant: MEDVET SCIENCE PTY. LTD.Inventors: Michael Paul Brown, Fares Al-Ejeh, Jocelyn Margaret Darby
-
Publication number: 20100104628Abstract: The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: March 28, 2008Publication date: April 29, 2010Applicant: Duke UniversityInventors: Susan M. Ludeman, Michael P. Gamcsik, Timothy A. Driscoll, James B. Springer, O. Michael Colvin, David J. Adams, Karel Base